OVARIAN CANCER and US: ProLindac

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label ProLindac. Show all posts
Showing posts with label ProLindac. Show all posts

Tuesday, April 03, 2012

financial: Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --



Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --

"....Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas......"